Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
Provider: Stock Traders Daily
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Idera Pharmaceuticals announces positive top-line data in phase 2 trial of IMO-8400

Friday, 28 Mar 2014 07:15am EDT 

Idera Pharmaceuticals Inc:Positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis.Primary objective of trial was to evaluate safety and tolerability of IMO-8400 over a 12-week treatment period, with a secondary objective to evaluate the clinical activity of IMO-8400.Trial met its primary objective as all treatments were well tolerated with no treatment related discontinuation, serious adverse events or dose reductions.IMO-8400 treatment met secondary objective of demonstrating clinical activity in patients with psoriasis, as assessed by Psoriasis Area and Severity Index (PASI).IMO-8400, which is Idera's lead clinical candidate, is an antagonist of Toll-like receptors (TLRs) 7, 8, and 9.Companies strategy is to develop IMO-8400 for the treatment of genetically defined forms of B-cell lymphoma and orphan autoimmune diseases. 

Company Quote

-0.27 -5.25%
27 Feb 2015